文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

验证REverSe TRanscrIptase Chain Termination检测法测量临床药代动力学试验干血斑中替诺福韦二磷酸

Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

在74份接受替诺福韦酯/恩曲他滨方案者的干血斑样本中,RESTRICT酶法检测替诺福韦二磷酸与LC-MS/MS金标准高度相关(r=-0.90;P<0.0001),对低、中、高依从性稳态基准浓度的分类AUC分别为0.974、0.936、0.955。该简易酶法可准确测量干血斑替诺福韦二磷酸,为替诺福韦酯方案提供可及的目标依从性监测。

要点

  • RESTRICT酶法与LC-MS/MS检测干血斑替诺福韦二磷酸高度相关(r=-0.90;P<0.0001)。
  • RESTRICT对低、中、高依从性稳态基准浓度分类AUC分别为0.974、0.936、0.955。
  • 该法使用简易流程和易得实验室设备,可准确测量干血斑替诺福韦二磷酸。

核心结论

  • 酶法RESTRICT检测可使用简易流程和易得实验室设备准确测量干血斑标本中替诺福韦二磷酸浓度。
  • 该法为接受替诺福韦酯为基础方案暴露前预防或抗逆转录病毒治疗者提供可及的目标依从性监测。

研究设计与样本

  • 研究对来自直接观察治疗研究中接受替诺福韦酯/恩曲他滨方案个体的74份干血斑样本进行RESTRICT检测。
  • 将RESTRICT检测结果与液相色谱串联质谱(LC-MS/MS)金标准方法比较。
  • 采用受试者工作特征曲线下面积(AUC)判定RESTRICT将干血斑替诺福韦二磷酸浓度正确分类至既定稳态依从性基准浓度的能力。

主要发现

  • RESTRICT检测干血斑样本结果与LC-MS/MS检测干血斑替诺福韦二磷酸结果高度相关(r=-0.90;P<0.0001)。
  • RESTRICT将干血斑样本正确分类至低依从性稳态基准浓度的AUC=0.974。
  • RESTRICT将干血斑样本正确分类至中依从性稳态基准浓度的AUC=0.936。
  • RESTRICT将干血斑样本正确分类至高依从性稳态基准浓度的AUC=0.955。

临床怎么用

  • 作者认为酶法RESTRICT检测可使用简易流程和易得实验室设备准确测量干血斑替诺福韦二磷酸浓度。
  • 作者认为该法为接受替诺福韦酯为基础暴露前预防或抗逆转录病毒治疗者提供可及的目标依从性监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir diphosphate concentration in red blood cells is an objective measure of long-term oral pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) adherence. However, current methods for measuring tenofovir diphosphate are equipment and capital intensive, limiting widespread adoption. OBJECTIVES: Low cost, rapid diagnostics for measuring tenofovir diphosphate may drive clinical adoption of routine drug level measurement as a tool for adherence monitoring of tenofovir disoproxil fumarate-based PrEP or ART. We validate a simple and accessible enzymatic assay [REverSe TRanscrIptase Chain Termination (RESTRICT)] for measuring tenofovir diphosphate in dried blood spots (DBS) obtained from a directly observed therapy study of individuals on PrEP. METHODS: We performed RESTRICT measurements on 74 DBS samples from individuals on tenofovir disoproxil fumarate/emtricitabine regimens. We compared RESTRICT measurements with those from a gold-standard method of liquid chromatography tandem mass spectrometry (LC-MS/MS). The ability of RESTRICT to correctly classify DBS tenofovir diphosphate concentrations to established steady-state adherence benchmark concentrations was determined using area under receiver operating characteristic curves (AUCs). RESULTS: The RESTRICT measurements of DBS samples were highly correlated with LC-MS/MS measurements of tenofovir diphosphate from DBS (r = -0.90; P < 0.0001). The RESTRICT assay correctly classified DBS samples as above or below established steady-state adherence benchmark concentrations corresponding to low (AUC = 0.974), moderate (AUC = 0.936) and high (AUC = 0.955) levels of adherence. CONCLUSIONS: The enzymatic RESTRICT assay can accurately measure tenofovir diphosphate concentrations in DBS specimens using simple procedures and readily available laboratory equipment, offering accessible objective adherence monitoring for persons receiving tenofovir disoproxil fumarate-based PrEP or ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sullivan BP, Craig CA, Bender AT, et al. Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial. J Antimicrob Chemother. 2025. PMID: 39995274. doi:10.1093/jac/dkaf049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。